New York Times(US:NYT) TMX Newsfile·2026-02-21 12:56Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical, Inc. due to allegations of securities law violations related to misleading statements and fraudulent activities [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Picard Medical between September 2, 2025, and October 31, 2025, to discuss their legal rights [1]. - There is an April 13, 2026, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Picard Medical [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [6]. Group 2: Allegations Against Picard Medical - The complaint alleges that Picard Medical and its executives violated federal securities laws by making false and misleading statements and failing to disclose critical information [4]. - Specific allegations include involvement in a fraudulent stock promotion scheme using social media misinformation and the use of offshore accounts for coordinated share dumping during a price inflation campaign [4]. - The company's public statements and risk disclosures reportedly omitted mention of false rumors and artificial trading activity that influenced the stock price [4]. Group 3: Stock Performance - On October 24, 2025, Picard Medical's shares closed at $5.31, a significant decline from $13.20 on October 23, 2025, representing a drop of $7.89 per share or approximately 59.8% in a single trading session [5].